How is asthma treated?

Asthma is a chronic inflammatory disorder of the airways characterized by variable and recurring symptoms, airflow obstruction, bronchial hyperresponsiveness, and underlying inflammation. Effective management requires a comprehensive, individualized approach grounded in evidence-based guidelines such as those from the Global Initiative for Asthma (GINA).

First-line treatment centers on inhaled corticosteroids (ICS), which reduce airway inflammation and lower the risk of exacerbations. For most patients with persistent asthma, a low-dose ICS is initiated and titrated based on symptom control and lung function. In patients aged 12 years and older with uncontrolled symptoms despite low-dose ICS, GINA recommends switching to as-needed low-dose ICS-formoterol (a combination of inhaled corticosteroid and rapid-onset long-acting beta₂-agonist) for both symptom relief and anti-inflammatory protection—replacing traditional short-acting beta₂-agonists (SABAs) used alone.

For moderate-to-severe asthma, treatment escalation may include adding a long-acting muscarinic antagonist (LAMA), increasing ICS dose (with caution due to systemic side effects), or introducing biologic therapies targeting specific inflammatory pathways—such as anti-IL-5 agents (e.g., benralizumab, mepolizumab, dupilumab) for eosinophilic asthma, or anti-IgE therapy (omalizumab) for allergic asthma. These biologics are reserved for patients with confirmed type 2 inflammation and frequent exacerbations despite optimized controller therapy.

Nonpharmacologic strategies are equally critical: identifying and avoiding triggers (e.g., allergens, tobacco smoke, occupational irritants), smoking cessation, annual influenza vaccination, pneumococcal vaccination when indicated, and structured asthma education—including proper inhaler technique, use of written asthma action plans, and regular follow-up to assess control, adjust therapy, and monitor for adverse effects.

Acute exacerbations require prompt intervention: supplemental oxygen (to maintain SpO₂ ≥90–94%), repeated doses of SABA via spacer or nebulizer, and early systemic corticosteroids (e.g., oral prednisone 40–50 mg daily for 5–7 days). Hospital referral is warranted for severe or life-threatening attacks, poor response to initial treatment, or significant comorbidities.

Long-term success hinges on shared decision-making, ongoing assessment of symptom control and risk factors (e.g., exacerbation history, lung function decline, medication adherence), and timely therapeutic adjustments—not just to relieve symptoms but to prevent irreversible airway remodeling and preserve lung health over time.